Literature DB >> 31763364

Bioinformatics analyses of publicly available NEPCa datasets.

Siyuan Cheng1, Xiuping Yu1.   

Abstract

Gene expression profiles are valuable resources for the identification of key players that driver disease progression. However, neuroendocrine prostate cancer (NEPCa) specimens are rare, limiting research on this aggressive disease. In this study, we generated a 12-gene signature of NEPCa and used this signature to differentiate NEPCa from prostate adenocarcinoma (AdPCa) samples in publicly available datasets. From these samples, we identified genes that were differentially expressed in NEPCa and AdPCa. Gene ontology and network analyses revealed key players in the pathogenesis of NEPCa, including E2Fs, members of MHC class II, and factors involved in neuron differentiation, neurogenesis, and stem cell signaling. In conclusion, we identified a 12-gene signature of NEPCa and found pathways that are important for the pathologic development of NEPCa. AJCEU
Copyright © 2019.

Entities:  

Keywords:  Neuroendocrine; prostate cancer; signature

Year:  2019        PMID: 31763364      PMCID: PMC6872473     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  35 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  Role of histone H3 lysine 27 methylation in Polycomb-group silencing.

Authors:  Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

3.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

4.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Authors:  Sheng Yu Ku; Spencer Rosario; Yanqing Wang; Ping Mu; Mukund Seshadri; Zachary W Goodrich; Maxwell M Goodrich; David P Labbé; Eduardo Cortes Gomez; Jianmin Wang; Henry W Long; Bo Xu; Myles Brown; Massimo Loda; Charles L Sawyers; Leigh Ellis; David W Goodrich
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

5.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

6.  Next-generation characterization of the Cancer Cell Line Encyclopedia.

Authors:  Mahmoud Ghandi; Franklin W Huang; Judit Jané-Valbuena; Gregory V Kryukov; Christopher C Lo; E Robert McDonald; Jordi Barretina; Ellen T Gelfand; Craig M Bielski; Haoxin Li; Kevin Hu; Alexander Y Andreev-Drakhlin; Jaegil Kim; Julian M Hess; Brian J Haas; François Aguet; Barbara A Weir; Michael V Rothberg; Brenton R Paolella; Michael S Lawrence; Rehan Akbani; Yiling Lu; Hong L Tiv; Prafulla C Gokhale; Antoine de Weck; Ali Amin Mansour; Coyin Oh; Juliann Shih; Kevin Hadi; Yanay Rosen; Jonathan Bistline; Kavitha Venkatesan; Anupama Reddy; Dmitriy Sonkin; Manway Liu; Joseph Lehar; Joshua M Korn; Dale A Porter; Michael D Jones; Javad Golji; Giordano Caponigro; Jordan E Taylor; Caitlin M Dunning; Amanda L Creech; Allison C Warren; James M McFarland; Mahdi Zamanighomi; Audrey Kauffmann; Nicolas Stransky; Marcin Imielinski; Yosef E Maruvka; Andrew D Cherniack; Aviad Tsherniak; Francisca Vazquez; Jacob D Jaffe; Andrew A Lane; David M Weinstock; Cory M Johannessen; Michael P Morrissey; Frank Stegmeier; Robert Schlegel; William C Hahn; Gad Getz; Gordon B Mills; Jesse S Boehm; Todd R Golub; Levi A Garraway; William R Sellers
Journal:  Nature       Date:  2019-05-08       Impact factor: 49.962

7.  SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.

Authors:  Yinan Li; Nilgun Donmez; Cenk Sahinalp; Ning Xie; Yuwei Wang; Hui Xue; Fan Mo; Himisha Beltran; Martin Gleave; Yuzhuo Wang; Colin Collins; Xuesen Dong
Journal:  Eur Urol       Date:  2016-05-11       Impact factor: 20.096

8.  Human ASH1 expression in prostate cancer with neuroendocrine differentiation.

Authors:  Ida Rapa; Paolo Ceppi; Enrico Bollito; Rosj Rosas; Susanna Cappia; Elisa Bacillo; Francesco Porpiglia; Alfredo Berruti; Mauro Papotti; Marco Volante
Journal:  Mod Pathol       Date:  2008-02-29       Impact factor: 7.842

9.  Causal analysis approaches in Ingenuity Pathway Analysis.

Authors:  Andreas Krämer; Jeff Green; Jack Pollard; Stuart Tugendreich
Journal:  Bioinformatics       Date:  2013-12-13       Impact factor: 6.937

10.  HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions.

Authors:  Hannah Brechka; Raj R Bhanvadia; Calvin VanOpstall; Donald J Vander Griend
Journal:  Genes Dis       Date:  2017-02-16
View more
  9 in total

1.  FOXA2 promotes prostate cancer growth in the bone.

Authors:  Zachary M Connelly; Renjie Jin; Jianghong Zhang; Shu Yang; Siyuan Cheng; Mingxia Shi; Justin Mm Cates; Runhua Shi; David J DeGraff; Peter S Nelson; Yunlong Liu; Colm Morrissey; Eva Corey; Xiuping Yu
Journal:  Am J Transl Res       Date:  2020-09-15       Impact factor: 4.060

2.  Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.

Authors:  Jing Wang; Jingjing Li; Lijuan Yin; Tianjie Pu; Jing Wei; Varsha Karthikeyan; Tzu-Ping Lin; Allen C Gao; Boyang Jason Wu
Journal:  Oncogene       Date:  2022-08-19       Impact factor: 8.756

3.  Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation.

Authors:  Elena Beketova; Sheng Liu; Jake L Owens; Qi Shen; Jogendra Singh Pawar; Andrew M Asberry; Jie Yang; Xuehong Deng; Bennett D Elzey; Timothy L Ratliff; Liang Cheng; Richard Choo; Deborah E Citrin; Thomas J Polascik; Bangchen Wang; Jiaoti Huang; Chenglong Li; Jun Wan; Chang-Deng Hu
Journal:  Mol Cancer Ther       Date:  2022-03-01       Impact factor: 6.009

4.  The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.

Authors:  Siyuan Cheng; Nestor Prieto-Dominguez; Shu Yang; Zachary M Connelly; Samantha StPierre; Bryce Rushing; Andy Watkins; Lawrence Shi; Meredith Lakey; Lyndsey Buckner Baiamonte; Tajammul Fazili; Aubrey Lurie; Eva Corey; Runhua Shi; Yunshin Yeh; Xiuping Yu
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-04-20       Impact factor: 5.554

5.  Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression.

Authors:  Siyuan Cheng; Shu Yang; Yingli Shi; Runhua Shi; Yunshin Yeh; Xiuping Yu
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379

Review 6.  Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression.

Authors:  Roosa Kaarijärvi; Heidi Kaljunen; Kirsi Ketola
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

7.  MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.

Authors:  Divya Bhagirath; Michael Liston; Nikhil Patel; Theresa Akoto; Byron Lui; Thao Ly Yang; Dat My To; Shahana Majid; Rajvir Dahiya; Z Laura Tabatabai; Sharanjot Saini
Journal:  Oncogene       Date:  2020-10-09       Impact factor: 9.867

8.  Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.

Authors:  Paola Ostano; Maurizia Mello-Grand; Debora Sesia; Ilaria Gregnanin; Caterina Peraldo-Neia; Francesca Guana; Elena Jachetti; Antonella Farsetti; Giovanna Chiorino
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

Review 9.  Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.

Authors:  Stefan Werner; Gunhild von Amsberg; Lina Merkens; Verena Sailer; Davor Lessel; Ella Janzen; Sarah Greimeier; Jutta Kirfel; Sven Perner; Klaus Pantel
Journal:  J Exp Clin Cancer Res       Date:  2022-02-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.